Stocks of Sarepta Therapeutics - Current price, Where to buy? Chart
| Detail | Data |
|---|---|
| Stocks: | Sarepta Therapeutics |
| ompany Name: | Sarepta Therapeutics, Inc. |
| Ticker: | SRPT |
| Exchange: | NasdaqGS |
| Outstanding stocks: | 94,505,600 |
| 24-hour Volume: | 2,074,713 |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Number of Employees: | 1314 |
| Country: | United States |
| City: | Cambridge |
| Address: | 215 First Street |
| P/E Ratio: | Forward P/E | EPS: | Forward EPS | Book value per share | Market capitalization |
|---|---|---|---|---|---|
| / | 12.57 | -5.81 USD | 10.39 USD | 10.17 USD | 12,345,267,200.00 USD |
| P/E Ratio: | / |
|---|---|
| Forward P/E: | 12.57 |
| EPS: | -5.81 USD |
| Forward EPS: | 10.39 |
| Book value per share: | 10.17 USD |
| Market capitalization: | 12,345,267,200.00 USD |
Sarepta Therapeutics
Fundamental Indicators
| Indicator | Data |
|---|---|
| Total Revenue: | 1,403,299,968.00 USD |
| Net Income: | 16,897,000.00 USD |
| Price-to-Book (P/B) Ratio: | 12.84 |
| PEG Ratio: | 0.56 |
Note: The data is approximate, subject to change over time, and may not be current; however, we strive for the highest possible accuracy.
Analysts' predictions
| Analysts | Recommendation |
|---|---|
| Issued Recommendation: | According to our data, the recommendation issued for Sarepta Therapeutics stocks is: buy |
| Number of Analysts: | 19 |
| Highest Target Price: | 224 USD |
| Lowest Target Price: | 128 USD |
| Average Target Price: | 166 USD |
Note: The data is approximate. Recommendations and price forecasts for Sarepta Therapeutics stocks based on analysts' ratings may change over time. Some recommendations may already be outdated and may not be accurate. We strongly advise against buying and selling stocks based on analysts' recommendations!
Dividend
| Dividends | Value |
|---|---|
| Dividend Amount | According to our data, the company Sarepta Therapeutics is currently not paying dividends. |
| Annual Yield %: | - |
| Ex-dividend Date: | - |
| Average % Yield for 5 Years: | - |
| Payout Ratio: | - |
| Value of Last Dividend Paid: | - |
| Date of Last Dividend: | - |
The dividend is displayed for the entire calendar year, however, it is usually paid out quarterly in parts. Data may change!
Where to Buy Sarepta Therapeutics Stocks?
If you're interested in investing in Sarepta Therapeutics stocks and believe in their future growth, you can purchase them through stock brokers like XTB or eToro. To make buying easier, we've prepared a table with offers from these brokers, including quick purchase of Sarepta Therapeutics stocks through mobile apps with client support. In this table, you can compare brokers offering real Sarepta Therapeutics stocks. Brokers providing the option to buy real stocks (not CFDs) are identified by "Real Stocks" in the comparison table column.
| Broker | Platforms | Regulation | Min. Deposit | Deposits / Withdrawals | CopyTrader | Real Stocks | Website Link |
|---|---|---|---|---|---|---|---|
 |
Proprietary platform, social network + CopyTrader™ | 100 USD | Bank transfer, credit cards, Skrill, PayPal, Neteller |
 Go to eToro
|
|||
 |
xStation, mobile version | 10 USD | Credit cards, Skrill, bank transfer |
 Go to XTB
|
|
|
| xStation, mobile version | Proprietary platform, social network + CopyTrader™ |
|
Go to XTB
|
Go to eToro
|
More Information about Sarepta Therapeutics (SRPT)
Sarepta Therapeutics consistently proves itself as a leader in its industry. Total revenues for the last 12 months exceed 1,403,299,968.00 USD, demonstrating its strong market position and ability to generate high revenues. Negative EBITDA of -52,995,000.00 USD may indicate challenges but also opportunities for Sarepta Therapeutics to invest in future growth. A higher debt-to-equity ratio of 1.45 indicates higher leverage for Sarepta Therapeutics compared to its equity, requiring cautious management. Gross margin of 25.66% indicates room for Sarepta Therapeutics to improve cost efficiency and competitiveness. Lower profit margin of 1.20% suggests opportunities for Sarepta Therapeutics to increase efficiency and reduce costs.
| Indicator | Value |
|---|---|
| Revenue, Debt, and Cash Flow | |
| Company Revenue: | 1,403,299,968.00 USD |
| EBITDA: | -52,995,000.00 USD - Negative EBITDA may signal financial challenges or growth investments. |
| Earnings Per Share: | -5.81 USD |
| Book Value Per Share: | 10.17 USD |
| Total Cash: | 1,390,743,040.00 USD |
| Total Cash per Share: | 14.71 USD |
| Total Debt: | 1,395,618,048.00 USD |
| Debt to Equity Ratio: | 1.45 |
| Quick Ratio: | 2.91 |
| Current Ratio: | 4.05 |
| Free Cash Flow: | -367,377,632.00 USD |
| Operating Cash Flow: | -533,672,992.00 USD |
| Company Margins | |
| Gross Margins: | 25.66 % |
| EBITDA Margins: | -3.78 % |
| Operating Margins: | 8.44 % |
| Profit Margins: | 1.20 % |
| Performance | |
| Return on Assets: | -1.9 % |
| Return on Equity: | 2.0 % |
| Earnings Growth (1 year): | / |
| Revenue Growth (1 year): | 63.1 % |
| Year-over-Year Quarterly Earnings Growth: | / |
| Valuation | |
| Market Capitalization: | 12,345,267,200.00 USD |
| Enterprise Value: | 12,378,036,224.00 USD |
| EV/Revenue: | 8.821 |
| EV/EBITDA: | -233.57 |
| Number of Shares and Short Shares | |
| Float Shares: | 90,357,158 shares |
| Shares Outstanding: | 94,505,600 shares |
| Held Percent Insiders: | 0.04 % |
| Held Percent Institutions: | 87.03 % |
| Shares Short: | 4,874,305 |
| Shares Short Prior Month: | 4,966,633 |
| Date Short Interest: | 2024-04-15 |
| Shares Percent Shares Out: | 5.19 % |
| Short Ratio: | 7.68 |
| Beta: | / |
| Short Percent of Float: | 5.42 % |
| Předpokládaný počet akcií: | 93,855,400 |
Frequently Asked Questions (FAQ)
According to our data, Sarepta Therapeutics does not currently pay dividends, even in 2024.
Sarepta Therapeutics shares are traded on the stock exchange NasdaqGS under the ticker symbol: SRPT. You can buy or trade them with a variety of stock brokers offering real stock trading services.
According to our data, there is a buy recommendation issued for Sarepta Therapeutics shares by a total of 19 analysts. The average target price prediction is 166 USD per share.
The total number of Sarepta Therapeutics shares on the exchange is 94,505,600.00, which, at the current market capitalization, values the company at 12,345,267,200.00 USD.
